






10/510119

1/28





10/510119

2/28

FIG. 2A
ANTI-CD40 Ab/
CD4-DEPLETEDFIG. 2B
CONTROL Ab/
CD4-DEPLETEDFIG. 2C
ANTI-CD40 Ab/
CLASS II KOFIG. 2D
CONTROL Ab/
CLASS II KO




10/510119

3/28



10/510119

4/28



10/510119

5/28

FIG.5A




FIG.5B




FIG.5C






FIG.5D




10/510119

6/28



10/510119

7/28



10/510119

8/28

FIG. 7C




FIG. 7D






FIG. 7E

10/510119


9/28



10/510119

10/28


Fig 9



10/510119

11/28

Fig 9




10 / 510119



12/28

Fig 10


a + anti-CD40 Ab



b BMDC/-



b BMDC/Poly I:C



B7.2


4-1BB

10/510119


13/28

Fig 11a


no treatment




anti-4-1BB Ab



E1A-peptide + control Ab



E1A-peptide + anti-4-1BB Ab




→ CFSE

14/28

101510119


Fig 11b



10/510119

15/28


Fig 12



10/510119

16/28


Fig 13



10/510119

17/28


Fig 14



18/28

10/510119


Fig 14e



10/510119

19/28


Fig 15

anti-4-1BB +
anti-rat-APC

20/28

10/510119


Fig 16



21/28



10/510119

Fig 17




10/510119

22/28



10/510119


Fig 18c



10/510119


24/28

Fig 19




10/510119

Fig 20



10/510119

Fig 21a



27/28

10/510119

Fig 21b





Fig 21c



28/28

10/510119

Fig 22




Fig 23

